Home › Graft-Versus-Host Disease
Graft-Versus-Host Disease clinical trials recruiting in the U.S.
36 studies for Graft-Versus-Host Disease are recruiting participants at sites across the United States.
Cities with the most studies
- Boston, MA9 studies
- New York City, NY8 studies
- Columbus, OH6 studies
- Queens, NY6 studies
- Washington, DC5 studies
- Atlanta, GA5 studies
- Baldwin Park, CA5 studies
- Miami, FL4 studies
- Tampa, FL4 studies
- Portland, OR4 studies
- Detroit, MI4 studies
- Houston, TX4 studies
- Seattle, WA4 studies
- St. Louis, MO4 studies
- Staten Island, NY4 studies
- New Rochelle, NY4 studies
- Edison, NJ4 studies
- Greenburgh, NY4 studies
- East Norwalk, CT4 studies
- Pittsburgh, PA4 studies
- Cleveland, OH3 studies
- Los Angeles, CA3 studies
- Nashville, TN3 studies
- Chicago, IL3 studies
By state
- California10 studies
- Florida7 studies
- Georgia5 studies
- Illinois3 studies
- Kansas3 studies
- Maryland5 studies
- Massachusetts9 studies
- Michigan5 studies
- Missouri4 studies
- New Jersey5 studies
- New York12 studies
- Ohio7 studies
- Oregon4 studies
- Pennsylvania6 studies
- Tennessee3 studies
- Texas5 studies
- Washington4 studies
Recently updated studies
Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant
RecruitingPhase 1
Ages 18 to 75 · All sexes · Updated Nov 9, 2026 · NCT06996119Parametric Response Mapping (PRM) for the Detection of Chronic Lung Injury in Hematopoietic Cell Transplant Recipients
RecruitingObservational study
36 Months · All sexes · Updated Nov 9, 2026 · NCT05866302Evaluation of Patients With Immune Function Abnormalities
RecruitingObservational studyHealthy volunteers welcome
All ages · All sexes · Updated Nov 9, 2026 · NCT00128973Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
RecruitingPhase 1/2
Ages 18 to 120 · All sexes · Updated Nov 6, 2026 · NCT05531786PTCy, Bortezomib and Sitagliptin for Prevention of GvHD Following Allogeneic HSCT
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 6, 2026 · NCT07675174Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
RecruitingObservational studyHealthy volunteers welcome
Ages 18 to 60 · All sexes · Updated Nov 6, 2026 · NCT00001529Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants
RecruitingObservational studyHealthy volunteers welcome
Ages 7 to 80 · All sexes · Updated Nov 5, 2026 · NCT00106925Ex Vivo-Expanded Regulatory T Cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic GVHD
RecruitingPhase 1
Ages 2 and older · All sexes · Updated Nov 4, 2026 · NCT06991361A Study of LBP-MARCO and Ruxolitinib in People With Graft-Versus-Host Disease (GVHD)
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT07913672Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT06434363A Study of Photobiomodulation (PBM) Therapy in People With Oral Graft-Versus-Host Disease (GVHD) After Stem Cell Transplant
RecruitingPhase 2
Ages 4 and older · All sexes · Updated Nov 2, 2026 · NCT05675930Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 27, 2026 · NCT07356245A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 22, 2026 · NCT06615050Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation
RecruitingPhase 2
Ages 60 and older · All sexes · Updated Oct 9, 2026 · NCT06799195Kinetic Analysis of Immune Cells in Blood and Chronic Graft-Versus-Host Disease-Affected Tissues After Allogeneic Hematopoietic Cell Transplantation
RecruitingObservational study
Ages 7 and older · All sexes · Updated Oct 5, 2026 · NCT07235501Vulvovaginal Graft-versus-Host Disease: Diagnosis and Microbiome Evaluation
RecruitingObservational study
Ages 18 to 70 · Women · Updated Sep 29, 2026 · NCT06649201Multidisciplinary Intervention for Adults With Chronic Graft-versus-host Disease
Recruiting
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06910969Vitamin A Supplementation in Allogeneic Stem Cell Transplantation.
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 24, 2026 · NCT06450925Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients With Medical Xerostomia
RecruitingPhase 1
Ages 18 to 90 · All sexes · Updated Aug 19, 2026 · NCT06392711Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT07565220Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 7, 2026 · NCT07216443A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 7, 2026 · NCT07359859A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jun 29, 2026 · NCT07006506Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Jun 29, 2026 · NCT06815003A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)
RecruitingPhase 2
Ages 2 and older · All sexes · Updated Jun 16, 2026 · NCT04710576From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.